There shall be twelve directors who, in addition to five officers, shall constitute the Board of Directors. There shall be balanced representation among academia, government and industry and voluntary health organizations on the Board of Directors. The Board of Directors shall manage the property and affairs of the Organization subject to these Bylaws.
OFFICERS
|
 |
President
Thomas P. Sutula, M.D., Ph.D.
University of Wisconsin - Madison |
 |
President Elect
TBD
|
 |
Secretary
TBD |
 |
Treasurer
Robert W. Hamill, M.D.
University of Vermont
College of Medicine,
Department of
Neurological Sciences
|
 |
Immediate Past President
Martha Morrell, M.D.
NeuroPace, Inc |
|
|
BOARD OF DIRECTORS
|
 |
Amy S. Chappell, M.D.
Naples, FL |

|
O’Neill D’Cruz, MD, MBA,
FAAN
OD Consulting and
Neurological Services, PLLC |
|
|
 |
Stewart A. Factor, DO
Emory University School
of Medicine |

|
Toby Ferguson, MD, PhD
Biogen Idec, Inc
|
|
|
 |
Bennett L, Lavenstein, MD
Co-Chair
Children’s Hospital Medical
Center |

|
John R. Richert, MD
Richert Partners
|
|
|

|
Steven Schachter, MD
CIMIT/Harvard Medical
School
|
|
|
|
|
EX-OFFICIO BOARD MEMBERS
|
 |
Development
Committee Chair
Martha Morrell, M.D.
NeuroPace, Inc |
 |
Neurotherapeutics®
Editor-in-Chief
M. Maral Mouradian, MD
Rutgers University |
 |
Program Committee
Chair
Stewart A. Factor, DO
Emory University School
of Medicine |
 |
NIH Blueprint Course
Liaison
Barbara Slusher, PhD, MAS
John Hopkins Brain Science
Institute |
 |
Federal Liaison
Amir Tamiz, PhD
NIH, NINDS, OTR |
 |
Program Committee
Co-Chair
C. Anthony Altar, PhD
Neuro Drug Consulting |
 |
Communications
Terrie Blalock, RN, MS
TBlalock Consulting |
 |
Communications
David Shoup
The Curry Rockefeller Group |
|
|
EXECUTIVE STAFF
|
 |
Executive Director
Jessica Keenan Smith
ASENT
|
|
|
|
|
|
|
|
|
|
|
|